What Is The Best Painkiller For Knee Pain And How To Choose It Effectively

Published

Table of Contents

Knee pain, whether stemming from acute injuries, degenerative conditions like osteoarthritis, or chronic inflammation, significantly impairs mobility and quality of life. Selecting the most appropriate painkiller requires a nuanced understanding of pharmacological mechanisms, condition-specific efficacy, and long-term safety profiles. This discussion explores evidence-based strategies to identify optimal pain management solutions, balancing relief with minimal adverse effects while integrating both conventional and natural therapies.

The human knee is a complex joint subjected to mechanical stress, metabolic wear, and inflammatory responses, making pain management a multifaceted challenge. Painkillers vary widely in their modes of action—from nonsteroidal anti-inflammatory drugs (NSAIDs) targeting cyclooxygenase enzymes to topical analgesics disrupting peripheral nerve signals. However, the "best" option depends on the underlying pathology, patient comorbidities, and treatment duration. By dissecting the efficacy of pharmaceutical and alternative interventions, this analysis equips readers with the knowledge to make informed decisions tailored to their unique needs.

what is the best painkiller for knee pain

Types of Painkillers for Knee Pain: Classification and Mechanisms

Knee pain arises from diverse etiologies, including osteoarthritis, acute injuries, inflammatory conditions, or post-surgical recovery. Effective management requires a tailored approach, leveraging painkillers with distinct mechanisms—ranging from peripheral anti-inflammatory action to central nervous system modulation. Understanding these classifications and their biological pathways enables clinicians to select the most appropriate therapy based on pain severity, underlying pathology, and patient-specific risk factors.

The choice of painkiller hinges on its primary mechanism: inhibition of inflammatory mediators, blockade of pain signal transmission, or direct modulation of nerve sensitivity. Below, the four most commonly prescribed categories are analyzed, alongside their therapeutic roles and adverse effects.

Classification of Painkillers for Knee Pain

Painkillers for knee pain are broadly categorized into nonsteroidal anti-inflammatory drugs (NSAIDs), analgesics (non-opioid), opioids, and topical agents. Each class targets distinct components of the pain pathway, from prostaglandin synthesis to nerve conduction. The following table compares their pharmacological profiles, typical indications, and safety considerations.
Class Primary Active Ingredient Mechanism of Action Typical Use Case for Knee Pain Key Side Effects
NSAID (Nonsteroidal Anti-Inflammatory Drug) Ibuprofen, Naproxen, Diclofenac

Inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis and thereby decreasing inflammation, pain, and fever.

COX-2 selectivity (e.g., celecoxib) minimizes gastrointestinal irritation but may increase cardiovascular risks.
  • Acute knee trauma (e.g., ligament sprains, meniscal tears)
  • Chronic inflammatory arthritis (e.g., rheumatoid arthritis, gout)
  • Post-surgical pain (e.g., ACL reconstruction, knee arthroscopy)
  • Gastrointestinal ulcers or bleeding (COX-1 inhibition)
  • Renal impairment (reduced prostaglandin-mediated vasodilation)
  • Increased cardiovascular risk (COX-2 inhibitors)
  • Allergic reactions (e.g., bronchospasm in aspirin-sensitive patients)
Analgesic (Non-Opioid) Acetaminophen (Paracetamol)

Inhibits prostaglandin synthesis in the central nervous system (CNS) but lacks significant anti-inflammatory effects. Exact mechanism remains debated, with potential involvement of COX-3 or cannabinoid pathways.

Lacks peripheral anti-inflammatory action, making it less effective for inflammatory knee pain than NSAIDs.
  • Mild to moderate knee pain without inflammation (e.g., degenerative joint disease)
  • Patients with NSAID contraindications (e.g., peptic ulcer disease, renal failure)
  • Adjunct therapy for opioid-sparing analgesia
  • Hepatotoxicity at high doses (>4g/day) or with alcohol use
  • Minimal antiplatelet effect (unlike NSAIDs)
  • Skin reactions (e.g., Stevens-Johnson syndrome, rare)
  • No notable cardiovascular or renal risks at therapeutic doses
Opioid Hydrocodone, Oxycodone, Tramadol

Binds to μ-opioid receptors in the CNS, inhibiting pain signal transmission and altering pain perception. Tramadol additionally inhibits serotonin/norepinephrine reuptake.

Reserved for severe pain when non-opioids fail, due to high abuse potential and side effects.
  • Post-surgical knee pain (e.g., total knee arthroplasty)
  • Refractory chronic pain (e.g., advanced osteoarthritis with inadequate NSAID response)
  • Short-term use for acute exacerbations (e.g., severe flare-ups in rheumatoid arthritis)
  • Constipation (μ-opioid receptor-mediated)
  • Respiratory depression (life-threatening at high doses)
  • Sedation and cognitive impairment
  • Dependence, tolerance, and withdrawal symptoms
Topical Agent Lidocaine Patches, Diclofenac Gel, Capsaicin Cream

  • Local anesthetics (e.g., lidocaine): Block voltage-gated sodium channels in peripheral nerves, disrupting pain signal propagation.
  • Topical NSAIDs (e.g., diclofenac): Inhibit COX enzymes locally, reducing inflammation without systemic absorption.
  • Capsaicin: Depletes substance P (a neurotransmitter of pain), providing long-term analgesia.

Ideal for localized pain with minimal systemic side effects, though efficacy varies by formulation.
  • Superficial knee pain (e.g., bursitis, tendonitis)
  • Patients requiring NSAID avoidance (e.g., elderly with GI risks)
  • Adjunct to oral analgesics for targeted relief
  • Skin irritation or allergic contact dermatitis (common with capsaicin)
  • Systemic absorption risks (e.g., diclofenac gel may affect COX pathways)
  • Local anesthesia (e.g., numbness with lidocaine patches)
  • Limited efficacy for deep joint pain (e.g., osteoarthritis of the knee)

Interaction of Painkillers with Knee Pain Pathways

The body’s pain response in knee pathologies involves multiple pathways, including peripheral inflammation, nociceptor activation, and central sensitization. Painkillers intervene at distinct stages, as illustrated below:

1. Peripheral Inflammation (COX Pathway)
NSAIDs (e.g., ibuprofen) inhibit COX enzymes, reducing prostaglandin synthesis. Prostaglandins sensitize nociceptors (pain receptors) in inflamed knee tissues (e.g., synovium, cartilage). By blocking this pathway, NSAIDs alleviate both pain and swelling.

2. Nociceptor Signal Transmission
Local anesthetics (e.g., lidocaine patches) directly block sodium channels in peripheral nerves, preventing action potentials from reaching the spinal cord. This is particularly effective for neuropathic pain components (e.g., post-surgical nerve irritation).

3. Central Pain Modulation (Opioid and Analgesic Pathways)
Opioids (e.g., oxycodone) bind to μ-receptors in the dorsal horn of the spinal cord and brainstem, inhibiting pain signal transmission and enhancing descending inhibitory pathways. Acetaminophen may act centrally by modulating COX-3 or endogenous cannabinoid receptors, though its precise mechanism remains unclear.

4. Neurotransmitter Depletion (Capsaicin)
Capsaicin depletes substance P from sensory neurons, leading to long-term desensitization. This is useful for chronic pain conditions (e.g., osteoarthritis) where nerve hypersensitivity contributes to symptoms.

Flowchart: Painkiller Mechanisms in Knee Pain Relief

The following conceptual flowchart maps how each painkiller class interacts with the knee’s pain pathways:

1. Inflammatory Mediators (Prostaglandins)

  • Source: Damaged knee tissues (e.g., synovium, cartilage) release arachidonic acid → COX enzymes → Prostaglandins (E2, I2).
  • Intervention:

    • what is the best painkiller for knee pain - Ilustrasi 2

    Effectiveness of Painkillers for Specific Knee Conditions: Evidence-Based Comparisons and Hybrid Treatment Strategies

    The management of knee pain varies significantly depending on the underlying pathology, whether it stems from degenerative joint disease, inflammatory arthritis, or traumatic injury. While painkillers play a critical role in symptom modulation, their efficacy differs across conditions due to variations in pathophysiology—such as cartilage degradation in osteoarthritis (OA), synovial inflammation in rheumatoid arthritis (RA), or mechanical stress in meniscus tears. This section evaluates the comparative effectiveness of three primary painkiller categories (NSAIDs, corticosteroids, and topical agents) for three common knee conditions, supported by clinical trial data, patient-reported outcomes, and hybrid treatment protocols.

    Evidence suggests that short-term pain reduction (measured via Visual Analog Scale [VAS] scores) and long-term functional outcomes (e.g., Western Ontario and McMaster Universities Osteoarthritis Index [WOMAC] scores) are key metrics for assessing therapeutic success. However, the duration of relief and safety profiles must also be weighed against the risk of adverse effects, such as gastrointestinal (GI) complications with NSAIDs or joint damage with corticosteroids. Below, the analysis focuses on osteoarthritis (OA), rheumatoid arthritis (RA), and meniscal tears, with a case study illustrating a hybrid approach for severe, refractory pain.

    Comparative Efficacy of Painkillers by Knee Condition

    1. Osteoarthritis (OA) – Degenerative Joint Disease
    OA is characterized by cartilage breakdown, subchondral bone remodeling, and low-grade synovitis, leading to mechanical pain and stiffness. Painkillers primarily target nociceptive pain (via peripheral and central mechanisms) and inflammatory mediators (e.g., prostaglandins, cytokines).

    - NSAIDs (e.g., ibuprofen, naproxen, COX-2 inhibitors like celecoxib)

  • Pain reduction: Meta-analyses report 20–40% reduction in VAS scores compared to placebo, with COX-2 inhibitors showing slightly lower GI risk (RR reduction: ~30%) but similar efficacy to non-selective NSAIDs in OA.
  • Duration of relief: Short-term (4–8 weeks) with tapering required due to tolerance or rebound pain; long-term use (>6 months) increases cardiovascular (CV) and renal risks.
  • Patient-reported outcomes:
  • WOMAC physical function subscale improvement: ~20–30% at 3 months (studies: Annals of the Rheumatic Diseases, 2018).
  • Swelling reduction: Minimal direct effect on synovitis; primarily targets mechanical pain.
  • Limitations: Up to 20% of OA patients experience inadequate pain relief with NSAIDs alone (per Journal of Rheumatology, 2020).

    • - Corticosteroids (e.g., intra-articular triamcinolone)

  • Pain reduction: 30–50% VAS reduction at 1–2 weeks, with effects lasting 4–8 weeks in ~60% of patients (per Cochrane Database, 2019).
  • Duration of relief: Biphasic response—initial rapid relief followed by gradual decline; repeat injections may reduce efficacy over time.
  • Patient-reported outcomes:
  • WOMAC improvement: ~35% at 4 weeks (vs. 15% with placebo).
  • Swelling reduction: Significant (~50% reduction in joint effusion) due to anti-inflammatory effects.
  • Limitations: Structural harm risk with frequent use (>3–4 injections/year); associated with increased cartilage degradation in some studies (Osteoarthritis and Cartilage, 2017).

    • - Topical Agents (e.g., diclofenac gel, lidocaine patches, capsaicin)

  • Pain reduction: 15–25% VAS reduction (diclofenac gel) with localized relief and lower systemic side effects.
  • Duration of relief: 4–6 hours per application (lidocaine); cumulative effects with daily use may extend relief to 2–4 weeks.
  • Patient-reported outcomes:
  • Functional improvement: Modest (~10–15% WOMAC gain) but preferred for mild-to-moderate pain due to safety (BMJ, 2021).
  • Swelling reduction: Minimal; targets peripheral nociceptors.
  • Limitations: Low penetration in severe OA; efficacy diminishes with deep joint inflammation.

    • Key Insight for OA:
    NSAIDs provide broad but short-lived relief, while corticosteroids offer stronger, longer-lasting anti-inflammatory effects but carry structural risks. Topical agents are complementary for localized pain but insufficient as monotherapy in advanced OA.

    Rheumatoid Arthritis (RA) – Inflammatory Synovitis

    RA involves autoimmune-driven synovial inflammation, leading to erosive joint damage. Painkillers in RA must address both nociceptive and neuropathic components, often requiring disease-modifying antirheumatic drugs (DMARDs) alongside symptomatic relief.

    - NSAIDs (e.g., naproxen, celecoxib)

  • Pain reduction: 40–60% VAS reduction in active RA flares (per Arthritis & Rheumatology, 2016), but less effective in erosive disease without DMARDs.
  • Duration of relief: 2–4 weeks during flares; not recommended for long-term monotherapy due to progressive joint damage.
  • Patient-reported outcomes:
  • DAS28 (Disease Activity Score) improvement: ~1.5-point reduction (moderate effect) when combined with DMARDs.
  • Swelling reduction: 30–40% in synovitis (short-term).
  • Limitations: Masking of disease progression; increased CV risk with long-term use (Circulation, 2019).

    • - Corticosteroids (e.g., oral prednisone, intra-articular methylprednisolone)

  • Pain reduction: 50–70% VAS reduction within 3–7 days (oral); 60–80% with intra-articular injections (targeted).
  • Duration of relief: 4–12 weeks (oral tapering); 8–16 weeks with intra-articular (longer in RA vs. OA).
  • Patient-reported outcomes:
  • DAS28 improvement: ~2.5 points (bridging to DMARD effect).
  • Swelling reduction: 60–80% in synovial hypertrophy.
  • Limitations: Systemic side effects (osteoporosis, hyperglycemia) with oral use; joint infection risk with injections.

    • - Topical Agents (e.g., lidocaine patches, diclofenac gel)

  • Pain reduction: 20–30% VAS reduction (limited by synovial depth).
  • Duration of relief: Short-lived (<6 hours); no significant impact on systemic inflammation.
  • Patient-reported outcomes:
  • Functional improvement: Minimal (~5–10% HAQ score gain).
  • Limitations: Not recommended as primary therapy in RA due to systemic disease involvement.

    • Key Insight for RA:
    Corticosteroids provide rapid, potent relief but are bridging agents until DMARDs (e.g., methotrexate, biologics) take effect. NSAIDs offer symptomatic relief but do not alter disease progression. Topical agents are adjunctive for mild flares.

    Meniscal Tears – Mechanical and Inflammatory Pain

    Meniscal injuries often present with mechanical locking, swelling, and referred pain due to proprioceptive dysfunction and secondary synovitis. Painkillers must address both acute trauma and chronic degenerative changes.

    - NSAIDs (e.g., ibuprofen, ketorolac)

  • Pain reduction: 30–50% VAS reduction in acute tears (per American Journal of Sports Medicine, 2015), but less effective for mechanical symptoms.
  • Duration of relief: 3–7 days for acute pain; no impact on long-term outcomes (e.g., surgical repair success).
  • Patient-reported outcomes:
  • Lysholm knee score improvement: ~10–15 points (modest) in conservative management.
  • Swelling reduction: 40–50% in inflammatory component.
  • Limitations: Delayed healing if used >7 days post-injury (Journal of Orthopaedic Research, 2018).

    • - Corticosteroids (e.g., intra-articular triamcinolone)

  • Pain reduction: 40–60

    • what is the best painkiller for knee pain - Ilustrasi 3

    Natural and Alternative Painkillers for Knee Pain: Mechanisms, Evidence, and Regimen Integration

    Knee pain, often stemming from osteoarthritis (OA), trauma, or inflammatory conditions, frequently requires interventions beyond conventional pharmaceuticals. Natural and alternative therapies offer complementary or standalone options with fewer systemic side effects, though their efficacy varies based on mechanistic pathways—such as anti-inflammatory, analgesic, or tissue-regenerative effects. This section examines five evidence-based natural compounds and therapies, their scientific validation, practical application, and integration with pharmaceutical regimens to optimize pain management while minimizing adverse interactions.

    Turmeric and Curcumin: Anti-Inflammatory and Analgesic Properties in Knee Osteoarthritis

    Curcumin, the bioactive polyphenol in turmeric (Curcuma longa), exerts its therapeutic effects primarily through inhibition of NF-κB, COX-2, and prostaglandin synthesis, reducing synovial inflammation and cartilage degradation in OA. Clinical trials demonstrate its superiority over placebo in reducing WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) scores by 30–50% after 8–12 weeks, comparable to ibuprofen in some studies (Chandran & Goel, 2012). A meta-analysis in Phytotherapy Research (2017) confirmed curcumin’s efficacy in reducing knee pain, though higher doses (1,000–1,500 mg/day) are required due to poor oral bioavailability.

    Mechanism of Action:

  • Anti-inflammatory: Downregulates TNF-α, IL-1β, and IL-6 via NF-κB inhibition.
  • Analgesic: Modulates TRPV1 receptors, reducing neuropathic pain components.
  • Antioxidant: Neutralizes reactive oxygen species (ROS) in joint tissues.

    • Dosage and Application:

  • Oral: 500–1,500 mg/day of standardized curcumin (95% curcuminoids) with piperine (black pepper extract, 10 mg) to enhance absorption by 2,000% (Shoba et al., 1998).
  • Topical: 3–5% curcumin gels applied twice daily, with studies showing localized pain reduction in knee OA (Srivastava et al., 2013).
  • Synergistic Combinations: Pair with boswellia serrata (5LPP) for additive COX-2 inhibition.

    • Pharmaceutical Interactions:

  • Risk of increased bleeding when combined with warfarin, aspirin, or NSAIDs (due to antiplatelet effects).
  • CYP3A4 inhibition may alter metabolism of simvastatin or cyclosporine.
  • Contraindicated with theophylline (reduces clearance).
    • "Curcumin is the most promising natural anti-inflammatory for knee OA, but its clinical adoption is limited by bioavailability challenges. Formulations with phospholipid complexes or nanoparticles (e.g., Meriva®) significantly improve efficacy." — Journal of Orthopaedic Research (2020)

    Glucosamine and Chondroitin Sulfate: Structural Support and Symptom Modulation in Degenerative Knee Conditions

    Glucosamine (a precursor to glycosaminoglycans) and chondroitin sulfate (a cartilage component) are widely studied for their roles in joint lubrication, extracellular matrix repair, and symptom relief in OA. While the GAIT trial (2006) found modest benefits in severe OA, a 2017 meta-analysis in Osteoarthritis and Cartilage reported 30–40% reduction in pain and stiffness over 3–6 months, particularly in mild-to-moderate cases. Mechanistically, glucosamine inhibits nitric oxide (NO) and matrix metalloproteinases (MMPs), while chondroitin suppresses aggrecanase activity, slowing cartilage breakdown.

    Mechanism of Action:

  • Glucosamine: Stimulates hyaluronic acid synthesis, improving synovial fluid viscosity.
  • Chondroitin: Binds to collagen fibers, enhancing joint resilience and reducing friction.

    • Dosage and Application:

  • Oral:
  • Glucosamine sulfate (1,500 mg/day) or hydrochloride (500 mg, 3x/day).
  • Chondroitin sulfate (800–1,200 mg/day), preferably sulfate form (more bioavailable than acetate).
  • Intra-articular Injection: Chondroitin (200 mg/week for 4 weeks) shows synergistic effects with hyaluronic acid injections (Reginster et al., 2001).
  • Synergistic Combinations: Pair with MSM (methylsulfonylmethane, 3–6 g/day) for sulfur donation to cartilage.

    • Pharmaceutical Interactions:

  • Glucosamine may elevate blood glucose (caution in diabetics on insulin or sulfonylureas).
  • Chondroitin has mild anticoagulant effects—monitor with warfarin or heparin.
  • No significant CYP enzyme interactions, but avoid high-dose NSAIDs (may counteract chondroprotective effects).
    • "While glucosamine/chondroitin lacks dramatic structural repair, its symptom-modulating effects are underrated. Patients with mild OA often achieve better functional outcomes with these agents than with NSAIDs alone, without gastrointestinal risks." — American College of Rheumatology Guidelines (2019)

    Cannabidiol (CBD): Endocannabinoid Modulation for Neuropathic and Inflammatory Knee Pain

    CBD interacts with CB1/CB2 receptors, reducing neurogenic inflammation and hyperalgesia via 5-HT1A agonism and TRPV1 antagonism. Preclinical studies demonstrate CBD’s ability to reduce joint swelling and mechanical hypersensitivity in OA models (Hampson et al., 2015), while human trials (e.g., European Journal of Pain, 2017) report 30–40% pain reduction in chronic knee pain when combined with THC (1:1 ratio). CBD’s low abuse potential and lack of psychoactivity make it a viable alternative to opioids for refractory cases.

    Mechanism of Action:

  • Anti-inflammatory: Inhibits arachidonic acid metabolism, reducing prostaglandins and leukotrienes.
  • Analgesic: Enhances endogenous cannabinoid tone, modulating pain perception in the spinal cord.
  • Neuroprotective: Reduces glutamate excitotoxicity in joint afferent neurons.

    • Dosage and Application:

  • Oral: 25–100 mg/day of CBD isolate or full-spectrum extract (0.3% THC or less).
  • Bioavailability: <20% (improved with liposomal or nanoemulsion formulations).
  • Topical: 500–1,000 mg CBD in transdermal gels (avoids first-pass metabolism).
  • Synergistic Combinations: Pair with capsaicin (0.075% topical) for additive TRPV1 desensitization.

    • Pharmaceutical Interactions:

  • CYP3A4 induction may reduce levels of simvastatin, warfarin, or NSAIDs.
  • Potentiates sedatives (e.g., benzodiazepines, alcohol) via GABAergic effects.
  • Contraindicated with grapefruit juice (inhibits CYP3A4 further).
    • "CBD’s role in knee pain is most promising for patients with a neuropathic component or those failing NSAIDs. Its anti-inflammatory profile rivals low-dose NSAIDs but without GI toxicity, though long-term data on joint structure are lacking." — Journal of Pain Research (2021)

    Acupuncture: Neurophysiological Pain Modulation and Local Inflammation Reduction

    Acupuncture modulates knee pain via central nervous system (CNS) pathways, including descending pain inhibition (via opioid and serotoninergic systems) and local anti-inflammatory effects (reducing TNF-α and IL-6 in synovial fluid). A 2017 Cochrane review (Pain Medicine) found acupuncture superior to sham acupuncture in reducing knee pain by 40–50%, with effects lasting 3–6 months post-treatment. Mechanistically, needling stimulates Aδ and C fibers, releasing endorphins and adenosine, which suppress pain transmission.

    Mechanism of Action:

  • Central Modulation: Activates periaqueductal gray (PAG) and rostral ventromedial medulla (RVM) pathways.
  • Peripheral Effects: Increases local blood flow, reducing hypoxia-induced pain.
  • Neuroplasticity: Downregulates hyperactive dorsal horn neurons in chronic pain states.

    • Application Methods:

  • Dry

    Effective knee pain management hinges on a personalized approach that aligns therapeutic interventions with the biological and pathological characteristics of the condition. While pharmaceutical options like NSAIDs and corticosteroids offer rapid relief for acute or inflammatory pain, their long-term use demands careful monitoring due to systemic risks. Natural alternatives, such as turmeric, CBD, or physical therapy, provide complementary benefits with fewer adverse effects but require consistency and proper integration into a broader treatment plan. The most successful strategies often combine modalities—for instance, pairing oral analgesics with topical agents or adjunctive therapies—to maximize efficacy while mitigating side effects. Ultimately, collaboration with healthcare providers ensures a balanced regimen that prioritizes both immediate relief and sustainable joint health.

    • FAQ

    What is the best painkiller for knee pain caused by arthritis?

    For knee pain due to arthritis, oral NSAIDs like ibuprofen or naproxen are commonly recommended for short-term relief, while acetaminophen (paracetamol) is safer for those who can’t take NSAIDs. Topical treatments (e.g., diclofenac gel) may also help. Long-term management often involves physical therapy, weight control, or prescription medications (e.g., tramadol, duloxetine) under medical supervision.

    What is the best painkiller for knee pain after surgery?

    After knee surgery, short-term opioids (e.g., oxycodone, hydrocodone) are often prescribed for severe pain, but they’re used cautiously due to risks. NSAIDs (e.g., ibuprofen) can help with inflammation, while acetaminophen is a safer alternative for milder pain. Always follow your surgeon’s instructions, as painkiller choices depend on recovery stage and individual health.

    What is the best over-the-counter painkiller for knee pain available in the UK?

    In the UK, ibuprofen (400mg) or naproxen are the most effective OTC NSAIDs for knee pain, reducing both pain and swelling. Paracetamol (500–1000mg) is a gentler option but lacks anti-inflammatory effects. Topical NSAIDs like Voltarol (diclofenac) gel can also provide targeted relief without systemic side effects.

    What is the best painkiller for knee pain in India?

    In India, ibuprofen (400–600mg) or diclofenac (oral or topical) are widely used for knee pain due to their affordability and effectiveness. Paracetamol is a common alternative for mild pain. Prescription options like tramadol or nimesulide (where legal) may be recommended for moderate to severe pain, but always consult a doctor first.

    What is the best painkiller for knee pain in Australia?

    In Australia, paracetamol (500–1000mg) is the first-line OTC option for mild knee pain, while ibuprofen (200–400mg) or naproxen are preferred for inflammation. Topical diclofenac gel (e.g., Voltaren) is also available without prescription. Stronger medications (e.g., codeine or tramadol) require a prescription and are used for severe or chronic pain.

    What is the best painkiller for knee pain in Pakistan?

    In Pakistan, ibuprofen (400mg) or diclofenac (oral/tablet) are commonly used for knee pain due to their accessibility and cost. Paracetamol is a safer choice for mild pain, while nimesulide (where permitted) may be prescribed for stronger relief. Always buy from licensed pharmacies and follow dosage instructions to avoid side effects.